27 June 2025 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
The objective was to compare the efficacy and safety of the use of aprotinin and tranexamic acid in cardiac surgery with cardiopulmonary bypass (CPB) in adult patients.Materials and methods. A randomized prospective comparative study was conducted. A total of 62 patients were included who underwent cardiac surgery with CPB. In order to prevent bleeding, fibrinolysis inhibitors were used intraoperatively in all patients, depending on the drug used, two groups were formed: «tranexamic acid» (n = 32) and «aprotinin» (n = 30). The time of the operation, the time of CPB and anoxia were recorded, postoperative blood loss according to 12-hour intervals and the need for transfusion during and after surgery were assessed. In the postoperative period, the need for inotropic support at the time of transfer to the intensive care unit (inotropic index), time of ALV, kidney (GFR, creatinine) and liver (ALT, direct bilirubin) function, as well as markers of the inflammatory response (white blood cell count, C-RP) were taken into account.Results. The volume of postoperative blood loss for 12 hours, as well as the need for transfusion in the intraoperative period, did not differ in the studied groups. At the same time, a decrease in the need for erythrocyte suspension was detected in the «aprotinin» group in the early postoperative period (p = 0.02). In the «aprotinin» group, the white blood cell count was higher than in the «tranexamic acid» group (p = 0.02), while the C-RP level was significantly lower in the “aprotinin” group (p = 0.002). The values of the PaO2 /FiO2 ratio in the studied groups did not differ, and the time of ALV was significantly lower in the «aprotinin» group (p = 0.016). Conclusion. The results of the study showed that the use of aprotinin during cardiac surgery with CPB reduces the need for transfusion of hemocomponents in the early postoperative period; no side effects were detected when using the drug.
21 April 2026 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
The objective was to assess the effect of a fixed-dose combination of Diclofenac and Orphenadrine (Neodolpasse®) on the effectiveness of pain relief and rehabilitation in the early postoperative period in patients undergoing knee arthroplasty. Materials and methods. The comparative prospective randomized study included 40 patients undergoing total knee replacement under combined anesthesia (spinal + saphenous block + iPACK block (the space between the popliteal artery and the capsule of the posterior part of the knee joint)). In the main group (n = 20), Neodolpasse® (a combination of 75 mg diclofenac and 30 mg orphenadrine in 250 ml of solution) was administered intravenously at the end of anesthesia, as well as in the postoperative period 2 times a day for 2 days. In the comparison group (n = 20), ketoprofen 100 mg was used instead of Neodolpasse® in the same way. The severity of pain was assessed using a visual analogue scale (VAS) before surgery and 6, 12, 24, and 48 hours after surgery. The need for additional narcotic analgesics was recorded. The assessment of patient’s recovery of weight-bearing function in the operated leg and their ability to actively move the knee joint was carried out by a rehab physician 24 hours after surgery. Results . The median VAS value in the main group after 6 hours was 5 [3; 6.75] points and was higher than in the comparison group (3 [1.75; 4), p = 0.004]. After 12 hours, the analgesic effect in the main group was better (3 [2; 5.75] versus 5.5 [4; 7], p = 0.03). No significant differences in the VAS values after 24 hours and 48 hours were found. Positive dynamics of recovery of active joint function after 24 hours was noted in 85% of patients in the main group and in 70% of the comparison group (p = 0.451). The need for additional administration of narcotic analgesics was recorded in 20% of patients in the main group (after 6 hours) and in 15% in the comparison group (but after 12 hours). No side effects or reactions were recorded. Conclusion . The analgesic effect of the diclofenac (75 mg) + orphenadrine (30 mg) combination after knee arthroplasty is comparable to that of ketoprofen (100 mg). Moreover, the use of this drug may facilitate the functional recovery in the operated leg in the early postoperative period.
26 August 2024 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
In cardiac surgery with cardiopulmonary bypass (CPB) is a common complication. The incidence of this complication in cardiac surgery patients is estimated at about 10%. For this reason, the introduction of a patient blood management (PBM) in cardiac surgery is extremely relevant. Antifibrinolytic therapy is a key pharmacological tool of a multimodal PBM in cardiac surgery with CPB. The use of antifibrinolytics (tranexamic acid (TXA) and epsilon aminocaproic acid (EACA)) is standard practice in complex cardiac surgery with CPB. However, there is currently ongoing discussion regarding the search for the optimal dose of EACA and TXA to achieve an effective concentration in blood plasma in order to inhibit fibrinolysis with the minimization of adverse events. The use of aprotinin has a number of potential advantages, but its use in routine clinical practice is significantly limited. This review presents modern approaches to antifibrinolytic therapy, examines the mechanisms of action of the main drugs, highlights the side effects associated with the use of antifibrinolytic agents.